Companies › Santen SAS
1 active drug program in 4 registered trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Infectious disease, Ophthalmology, Respiratory.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Oxymetazoline (STN1013800) Adrenergic receptor alpha agonist | ADRA1A, ADRA2A, ADRA2C, ADRA1D, ADRA1B | Phase 3 | Acquired Blepharophimosis; Sleep Apnea; Perioperative Respiratory Adverse Events; Nasal Obstruction | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02630121 | Oxymetazoline (STN1013800) | Phase 4 | Sleep Apnea | Respiratory | Apr 2026 |
| NCT06514612 | Oxymetazoline (STN1013800) | Phase 3 | Acquired Blepharophimosis | Ophthalmology | Aug 2026 |
| NCT06830109 | Oxymetazoline (STN1013800) | Phase 2 | Nasal Obstruction | Respiratory | Dec 2026 |
| NCT07000877 | Oxymetazoline (STN1013800) | Phase 4 | Perioperative Respiratory Adverse Events | Infectious disease | May 2028 |
Guangzhou Novaken Pharm Alimera Sciences Alcon Research VivaVision Biotech Materia Medica Holding
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.